Vadim Krivokrysenko

Vadim Krivokrysenko has a strong scientific and research background. Vadim started their career as a Graduate Student at the University of Illinois at Chicago, where they worked from 1996 to 2000. Following this, they worked as a Consultant at Quark Pharmaceuticals Inc from 1999 to 2002.

In 2000, Vadim joined the Cleveland Clinic as a Graduate Student, and later became a Postdoctoral Fellow, working there until 2007. During their time at Cleveland Clinic, they gained valuable experience in the field.

In 2003, Vadim started their career at Cleveland Biolabs as a Consultant and later transitioned to the role of R&D Project Director, where they worked from 2005 to 2011. In this role, they played a key role in the development and implementation of various projects.

Vadim then served as the R&D Senior Director at Cleveland Biolabs from 2012 to 2013, before being promoted to Vice President of Preclinical Development in 2014. In this position, they led the development of CBLB502 (Entolimod), a novel radiation medical countermeasure, and made significant contributions to the IP portfolio. Vadim also designed and supervised numerous preclinical studies, including efficacy, toxicology, and pharmacokinetics.

Overall, Vadim Krivokrysenko has a diverse and extensive work experience in the scientific and research field, with significant contributions in project management, preclinical development, and IP portfolio development.

Vadim Krivokrysenko completed their Master's degree in Molecular Biology at Lomonosov Moscow State University (MSU) from 1991 to 1996. Vadim further pursued their education and obtained a Ph.D. in Molecular Genetics from the University of Illinois Chicago, where they studied from 1996 to 2003.